0001121702-21-000010 | 10-K | XBRL Viewer

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2020	Mar. 12, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-33133
Entity Registrant Name	YIELD10 BIOSCIENCE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3158289
Entity Address, Address Line One	19 Presidential Way
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01801
City Area Code	617
Local Phone Number	583-1700
Title of 12(b) Security	Common Stock
Trading Symbol	YTEN
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 9,581,299
Entity Common Stock, Shares Outstanding		4,865,335
Documents Incorporated by Reference [Text Block]	DOCUMENTS INCORPORATED BY REFERENCE Pursuant to General Instruction G to Form 10-K, the information required by Part III, Items 10, 11, 12, 13 and 14 is incorporated herein by reference from the Company's proxy statement for the Annual Meeting of Stockholders to be held on May 24, 2021, which is expected to be filed not later than 120 days after the fiscal year end covered by this Form 10-K.
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Central Index Key	0001121702

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 3,423	$ 5,417
Short-term investments	6,279	5,700
Accounts receivable	86	72
Unbilled receivables	27	20
Prepaid expenses and other current assets	527	475
Total current assets	10,342	11,684
Restricted cash	264	332
Property and equipment, net	921	1,243
Right-of-use assets	2,712	3,141
Other assets	283	318
Total assets	14,522	16,718
Current Liabilities:
Accounts payable	60	279
Accrued expenses	1,297	1,326
Lease liabilities	457	602
Total current liabilities	1,814	2,207
Lease liabilities, net of current portion	3,163	3,619
Warrant liability (Note 9)	0	14,977
Other liabilities	13	0
Total liabilities	4,990	20,803
Commitments and contingencies (Note 7)
Series B Convertible Preferred Stock ($0.01 par value per share); 0 and 5,750 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively (Note 9)	0	0
Stockholders' Equity (Deficit):
Series A Convertible Preferred Stock ($0.01 par value per share); 0 and 796 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at December 31, 2020 and 2019, respectively, and 3,334,048 and 933,423 shares issued and outstanding at December 31, 2020 and 2019, respectively	33	9
Additional paid-in capital	384,758	360,926
Accumulated other comprehensive loss	(159)	(126)
Accumulated deficit	(375,100)	(364,894)
Total stockholders' equity (deficit)	9,532	(4,085)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 14,522	$ 16,718

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Series B Convertible Preferred Stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Series B Convertible Preferred Stock, shares issued (in shares)	0	5,750
Series B Convertible Preferred Stock, shares outstanding (in shares)	0	5,750
Preferred stock, par value per share (in dollars per share)	$ 0.01
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued	3,334,048	933,423
Common stock, shares outstanding	3,334,048	933,423
Series A Convertible Preferred Stock
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	796	0
Preferred stock, shares outstanding	796	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 799	$ 806
Expenses:
Research and development	5,361	4,848
General and administrative	5,047	4,554
Total expenses	10,408	9,402
Loss from operations	(9,609)	(8,596)
Other income (expense):
Loss on issuance of securities (Note 9)	0	(13,018)
Offering costs (Note 9)	0	(1,254)
Change in fair value of warrants (Note 9)	(957)	9,541
Loan forgiveness income (Note 12)	333	0
Other income (expense), net	83	117
Total other income (expense)	(541)	(4,614)
Net loss from operations before income taxes	(10,150)	(13,210)
Income Tax Expense (Benefit)	(56)	254
Net loss	$ (10,206)	$ (12,956)
Basic and Diluted net loss per share (in dollars per share)	$ (4.30)	$ (35.50)
Number of shares used in per share calculations:
Basic and Diluted (in shares)	2,373,265	364,967
Grant revenue
Revenue:
Total revenue	$ 799	$ 806

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (10,206)	$ (12,956)
Other comprehensive income (loss):
Change in foreign currency translation adjustment	(33)	(16)
Total other comprehensive loss	(33)	(16)
Comprehensive loss	$ (10,239)	$ (12,972)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (10,206)	$ (12,956)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	182	203
Loss on issuance of securities	0	13,018
Change in fair value of warrants	957	(9,541)
Loan forgiveness income (Note 12)	(333)	0
Loss on disposal of fixed assets	206	0
Expense for 401(k) company common stock match	109	98
Stock-based compensation	739	656
Noncash lease expense	429	1,625
Deferred tax asset	56	(254)
Changes in operating assets and liabilities:
Accounts receivable	(14)	22
Unbilled receivables	(7)	46
Prepaid expenses and other assets	(69)	9
Accounts payable	(219)	162
Accrued expenses	99	502
Other liabilities	13	0
Lease liabilities	(601)	(2,244)
Net cash used in operating activities	(8,659)	(8,654)
Cash flows from investing activities
Purchase of property and equipment	(76)	(61)
Proceeds from sale of property and equipment	10	0
Purchase of investments	(9,279)	(5,704)
Proceeds from sale and maturity of short-term investments	8,700	2,750
Net cash used by investing activities	(645)	(3,015)
Cash flows from financing activities
Proceeds from warrants exercised	1,658	0
Proceeds from PPP loan (Note 12)	333	0
Proceeds from securities offerings, net of issuance costs (Note 9)	5,305	14,083
Taxes paid on employees' behalf related to vesting of stock awards	(17)	(4)
Net cash provided by financing activities	7,279	14,079
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(37)	(16)
Net (decrease) increase in cash, cash equivalents and restricted cash	(2,062)	2,394
Cash, cash equivalents and restricted cash at beginning of period	5,749	3,355
Cash, cash equivalents and restricted cash at end of period	3,687	5,749
Supplemental Cash Flow Disclosure:
Interest paid	$ 8	$ 7

CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Warrants	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Registered direct offering	Registered direct offering Common Stock	Registered direct offering Additional Paid-In Capital	Public offering	Public offering Common Stock	Public offering Additional Paid-In Capital	Series A Convertible Preferred Stock	Series A Convertible Preferred Stock Preferred Stock	Series A Convertible Preferred Stock Common Stock	Series A Convertible Preferred Stock Common Stock Warrants	Series A Convertible Preferred Stock Additional Paid-In Capital	Series A Convertible Preferred Stock Additional Paid-In Capital Warrants	Series A Convertible Preferred Stock Public offering Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock Common Stock	Series B Convertible Preferred Stock Additional Paid-In Capital
Balance at Dec. 31, 2018	$ 5,698		$ 3	$ 357,743	$ (110)	$ (351,938)								$ 0
Balance (in shares) at Dec. 31, 2018			250,631											0
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	521			521
Issuance of common stock for 401(k) match	$ 89			89
Issuance of common stock for 401k match (in shares)	2,885		2,885
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ (4)			(4)
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)			116
Issuance of stock							$ 2,583		$ 2,583	$ 0	$ 4	$ (4)
Issuance of stock (in shares)								60,541			405,750								2,504
Issuance of common stock													$ 0		$ 2		$ (2)
Issuance of common stock (in shares)														(1,708)	213,500
Effect of foreign currency translation	(16)				(16)
Net loss	(12,956)					(12,956)
Balance at Dec. 31, 2019	(4,085)		$ 9	360,926	(126)	(364,894)								$ 0
Balance (in shares) at Dec. 31, 2019			933,423											796
Series B Convertible Preferred Stock, balance at Dec. 31, 2018	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2018	0
Increase (Decrease) in Temporary Equity
Issuance of preferred stock in connection with private offering (in shares)										5,750
Series B Convertible Preferred Stock, balance at Dec. 31, 2019	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2019	5,750
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	$ 864			864
Issuance of common stock for 401(k) match	$ 112			112
Issuance of common stock for 401k match (in shares)	20,788		20,788
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ (17)			(17)
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)			6,006
Issuance of stock	5,305	$ 1,658	$ 13	5,292												$ 2		$ 1,656
Issuance of stock (in shares)			1,348,285													207,296
Issuance of common stock													$ 0		$ 2		$ (2)			$ 0	$ 7	$ (7)
Issuance of common stock (in shares)														(796)	99,500						718,750
Effect of foreign currency translation	(33)				(33)
Net loss	(10,206)					(10,206)
Balance at Dec. 31, 2020	$ 9,532		$ 33	384,758	$ (159)	$ (375,100)								$ 0
Balance (in shares) at Dec. 31, 2020			3,334,048											0
Increase (Decrease) in Temporary Equity
Issuance of common stock upon conversion of Series B Convertible Preferred Stock	(5,750)
Reclassification of warrant liability to equity	$ 15,934			$ 15,934
Series B Convertible Preferred Stock, balance at Dec. 31, 2020	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2020	0

CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Offering costs	$ 425	$ 349

Nature of Business and Basis of Presentation	12 Months Ended
Nature of Business and Basis of Presentation	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the "Trait Factory", to develop improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada. The Company's goals are to efficiently develop and commercialize a high value crop products business by developing superior varieties of Camelina for the production of feedstock oils, nutritional oils, and PHA bioplastics, and to license its yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December 31, 2020. During the year ended December 31, 2020, the Company was successful in raising adequate capital to fund its operations, ending the year with unrestricted cash, cash equivalents and short-term investments of $9,702. Subsequent to year-end, on February 3, 2021, the Company raised a further $11,996 in cash, net of estimated offering costs of $744, through the sale of 1,040,000 shares of common stock at an issuance price of $12.25. Also subsequent to year-end, and through March 15, 2021, 481,973 of the Company's outstanding warrants issued in its November 2019 securities offering were exercised by warrant holders providing the Company with additional cash of $3,856. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management may be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on its current cash forecast, including funds received after year-end from its common stock offering and the exercise of warrants, management has determined that the Company's present capital resources will be sufficient to fund its planned operations for at least one year from when these financial statements are issued. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ("COVID-19") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of Consolidation

The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.

Reverse Stock Split

On January 15, 2020, the Company effected a 1-for-40 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed consolidated balance sheets included herein:


	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	3,423	$	5,417
Restricted cash	264		332
Total cash, cash equivalents and restricted cash	$	3,687	$	5,749

Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at December 31, 2020 and $332 at December 31, 2019, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.

Investments

Short-term investments represent holdings of available-for-sale marketable debt securities in accordance with the Company's investment policy. The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no long-term investments at December 31, 2020 and December 31, 2019.

Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and certain changes in stockholders' equity (deficit) that are excluded from net income (loss). The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive income (loss).

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, short-term investments and accounts receivable. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.

The Company's receivables related to U.S. and Canadian government grants are believed to have a low risk of default. At December 31, 2020, the Company's accounts and unbilled receivables of $113 include $27 due from Michigan State University for support to a Department of Energy funded grant under which the Company serves as a subcontractor and $86 is due from National Research Council Canada under a Canadian government research assistance grant administered through the Industrial Research Assistance Program. At December 31, 2019, $62 of the Company's total billed and unbilled receivables of $92 were from grants with the U.S. government.

Fair Value Measurements

The carrying amounts of the Company's financial instruments as of December 31, 2020 and December 31, 2019, which include cash equivalents, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 4 for further discussion on fair value measurements.

Segment Information

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. As of December 31, 2020, and December 31, 2019, less than 10% of the Company's combined total assets were located outside of the United States. During the years ended December 31, 2020 and December 31, 2019, the reported net loss from the Company's foreign subsidiaries was less than 10% of the combined net loss of the consolidated Company.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Repairs and maintenance are charged to operating expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.

Grant Revenue

The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor. These grants are considered an ongoing major and central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December 31, 2020 and December 31, 2019. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.

Research and Development

All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, product trials, facility related expenses, depreciation, and stock-based compensation. Costs incurred in connection with government research grants are recorded as research and development expenses.

General and Administrative Expenses

The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation expenses and office related expenses incurred to support the administrative operations of the Company.

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.

Basic and Diluted Net Loss per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, such as the Company's fiscal years ending December 31, 2020 and 2019, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect in the calculation of loss per share; meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.

The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net income per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders to be allocated between common and participating securities based on their respective rights to receive dividends. In periods of net loss, a participating security that does not have a contractual obligation to share in the loss is not allocated a portion of the net loss when determining loss per share under the two-class method. During November 2019, the Company completed an offering of its securities that included Series A Convertible Preferred Stock and Series B Convertible Preferred Stock meeting the definition of participating securities (See Note 9). However, due to the Company's net losses reported for the years ended December 31, 2020 and December 31, 2019, no allocation of the losses were allocated to the preferred shares as the holders of the preferred shares did not have a contractual obligation to fund losses. The loss per share for each year has been computed and presented based on the loss being fully assigned to the Company's weighted average outstanding common shares during the respective years.

The Company's calculation of basic and diluted loss per share for the year ended December 31, 2020 excludes 1,040,000 shares of common stock issued on February 3, 2021, in connection with a completed public stock offering. It also

excludes 481,973 shares of common stock issued after December 31, 2020 from the exercise of outstanding warrants by warrant holders. See Note 17 - Subsequent Events.

The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units, convertible preferred stock and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the years ended December 31, 2020 and 2019, respectively, are shown below:


	Year Ended December 31,
	2020	2019
Options	218,964	54,430
Restricted stock awards	11,775	42
Series A Convertible Preferred Stock	12,737	18,420
Series B Convertible Preferred Stock	31,421	82,705
Warrants	2,843,699	180,467
Total	3,118,596	336,064

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.

The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.

See Note 13 for further discussion of income taxes. The Company had no amounts recorded for any unrecognized tax benefits as of December 31, 2020 and 2019.

Recent Accounting Standards Changes

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. During the year ended December 31, 2020, the Company adopted the following new accounting guidance.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for the Company on January 1, 2020 and did not have a material impact on its disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows:

•Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;

•Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and

•Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

This standard became effective on January 1, 2020. However, since the Company is not currently participating in any collaborative arrangements, the new standard does not impact its financial statements.

The following new pronouncement is not yet effective but may impact the Company's financial statements in the future.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on the Company’s condensed consolidated financial statements.

Investments

12 Months Ended

Dec. 31, 2020

Investments, Debt and Equity Securities [Abstract]

Investments

INVESTMENTS

The Company's investments consist of the following:


	Accumulated Cost at December 31, 2020		Unrealized				Market Value at December 31, 2020
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	6,279	$	—	$	—	$	6,279
Total	$	6,279	$	—	$	—	$	6,279


	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. In addition, during November 2019 the Company issued Series A Warrants and Series B Warrants in its concurrent securities offerings that were considered free standing financial instruments, that were legally detachable and separately exercisable from the common and preferred stock issued in the two offerings (see Note 9). The Company determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and recognized at their inception date fair value due to the insufficiency of common shares available to permit their exercise. The warrant liability met Level 3 classification criteria for classification within the fair value hierarchy. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.

The Company’s financial assets classified as Level 2 at December 31, 2020 and December 31, 2019 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December 31, 2020 and December 31, 2019.

The $14,977 fair values of the Series A and Series B Warrant liability at December 31, 2019 was determined using the Black-Scholes valuation model. The expected volatility and the risk free discount rate used in the Black-Scholes model were determined based on the Company's historical market price published by the Nasdaq Capital Market and from published U.S. Treasury yield curves, respectively, for a period matched to the contractual term of each warrant series.


At December 31, 2019	Series A Warrants	Series B Warrants
Fair market of common stock (per share)	$6.86	$6.86
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

On January 15, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to effect a 1-for-40 reverse stock split. As a result of the reverse stock split, the Company's number of authorized but unissued shares of Common Stock increased significantly and the Series A Warrants and Series B Warrants issued under the offerings completed in November 2019 became eligible for exercise. Prior to reclassification as equity on January 15, 2020, the Company adjusted the warrant liability to its then $15,934 fair value using the assumptions below, recording a loss on the adjustment to fair value of $957.


At January 15, 2020	Series A Warrants	Series B Warrants
Fair market of common stock (per share)	$3.77	$3.77
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.


	Fair value measurements at December 31, 2020
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2020
Assets
Cash equivalents:
Money market funds	$	2,873	$	—	$	—	$	2,873

Short-term investments:
U.S. government and agency securities	—		6,279		—		6,279
Total assets	$	2,873	$	6,279	$	—	$	9,152


	Fair value measurements at December 31, 2019
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977

There were no transfers of financial assets or liabilities between category levels for the years ended December 31, 2020 and December 31, 2019.

The following tables show a reconciliation of the beginning and ending balances for the Level 3 warrant liability for each of the years ending December 31, 2020 and December 31, 2019. The Company's warrant liability was initially recorded in connection with the Company's concurrent public and private securities offerings completed during the year ended December 31, 2019. See Note 9 for more detailed information.


	Year ended December 31,
	2020		2019
Warrant liability, beginning of year	$	14,977	$	—
Warrants issued and classified as Level 3	—		24,518
Recognized gain (loss) from mark-to-market adjustment at December 31, 2019 balance sheet date	—		(9,541)
Recognized gain (loss) from mark-to-market adjustment prior to reclassification of warrant liability to equity	957		—
Reclassification from warrant liability to equity	(15,934)		—
Warrant liability, end of year	$	—	$	14,977

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment consist of the following:


	Year ended December 31,
	2020		2019
Equipment	$	766	$	852
Furniture and fixtures	43		119
Leasehold improvements	1,414		1,748
Software	22		53
Total property and equipment, at cost	2,245		2,772
Less: accumulated depreciation	(1,324)		(1,529)
Property and equipment, net	$	921	$	1,243

Depreciation expense for the years ended December 31, 2020 and December 31, 2019, was $182 and $203, respectively.

Accrued Expenses

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:


	Year ended December 31,
	2020		2019
Employee compensation and benefits	$	620	$	669
Leased facilities	188		51
Professional services	235		327
Other	254		279
Total accrued expenses	$	1,297	$	1,326

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contractual Commitments Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted") On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company will pay Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $219 remains outstanding as of December 31, 2020. As part of the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement. License Agreement with the University of Massachusetts ("UMASS") Pursuant to a license agreement with UMASS dated as of June 30, 2015 and subsequently amended, the Company has an exclusive, worldwide license under certain patents and patent applications, including issued patents covering the Company's yield trait gene C3003, relating to the manufacture of plants with enhanced photosynthesis. The agreement provides an exclusive, worldwide license to make, have made, use, offer for sale and import any transgenic plant seed or plant grown from transgenic plant material for sale to a farmer or grower that is derived from (in whole or in part) one or more issued or pending claims of the licensed patents or patent applications. Pursuant to the UMASS license agreement, the Company is required to use diligent efforts to develop licensed products throughout the field of use and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the agreement would give UMASS the right to terminate the agreement, following a notice period, unless the Company is able to reach agreement with UMASS as to a potential adjustment to the applicable milestone. The Company is obligated to pay UMASS milestone payments relating to regulatory filings and approvals covered by the agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense income, if any, related to the licensed products. The Company or UMASS may terminate the agreement in accordance with the terms of the agreement. License Agreement with the University of Missouri ("UM") Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops. Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone. The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement. Facility Leases The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 11. Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations. Guarantees As of December 31, 2020, and December 31, 2019, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2020 and December 31, 2019.

License Agreements	12 Months Ended
License Agreements	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	License Agreements In August 2020 the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specialized in plant genetics, to evaluate novel traits in soybean. Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability. The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future. In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato. Under the agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability. In September 2018, the Company granted a non-exclusive license to Forage Genetics International, LLC ("Forage Genetics"), a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum. The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform, C4001, C4002, C4003 and C4029. The key objective of the licensing agreement is to provide Forage Genetics with novel traits to test alone and/or in any combination in sorghum that may lead to the identification of new yield traits for potential future licensing from the Company for development and commercial deployment. In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean. Under this license, Bayer has the non-exclusive right to begin work with C3003 in its soybean program as a strategy to improve seed yield. Bayer may also conduct research with the Company's C3004 yield trait, a trait accessible through genome editing, in combination with C3003 to evaluate the effectiveness of the combination in improving seed yield in soybean. In August 2019, the Company expanded its 2017 non-exclusive research license with Bayer, for soybean crop research to include a new discovery related to its C3004 yield trait gene. None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.

Capital Stock and Warrants

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Capital Stock and Warrants

Common Stock

Registered Public Offering

On August 26, 2020, the Company completed a public offering of 835,000 shares of its common stock at a public

offering price of $4.25 per share. In addition, the underwriter exercised its over-allotment option to purchase 116,835 shares of common stock at the same price for total gross proceeds of $4,045 before issuance costs of $425.

Private Placement

Concurrent with the registered public offering described above, the Company completed a separate private placement offering of 396,450 shares of its common stock on August 26, 2020 to certain existing shareholders at the same $4.25 price offered to investors in the public offering. Proceeds from this private placement were $1,685.

Reverse Stock Split

On January 15, 2020, the Company completed a 1-for-40 reverse stock split ("reverse stock split") of its common stock by filing a certificate of amendment (the "Charter Amendment") with the State of Delaware to amend its certificate of incorporation. The ratio for the reverse stock split was determined by the Company's board of directors following approval by stockholders at the Company's special meeting held on January 9, 2020. The reverse stock split had the effect of increasing the Company's common shares available for issuance by reducing issued and outstanding common shares by a divisible factor of 40 while its authorized shares remained at its current 60 million shares. Proportional adjustments were made to the Company's outstanding stock options and to the number of shares issued and issuable under the Company's equity compensation plans.

November 2019 Concurrent Securities Offerings

On November 19, 2019, the Company closed on concurrent public and private securities offerings, receiving combined gross cash proceeds of $11,500, before issuance costs of $1,254.

The public portion of the offering included sales of Class A Units or Class B Units as follows:

•405,750 Class A Units priced at a public offering price of $8.00 per unit, with each unit consisting of one share of common stock, par value $0.01 per share, a Series A Warrant to purchase one share of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and a Series B Warrant to purchase one share of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The 405,750 Class A Units sold included the full exercise of the underwriter's over-allotment option of 93,750 Class A Units.

•2,504 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of Series A Convertible Preferred Stock, par value $0.01 per share, convertible at any time at the holder's option into 125 shares of common stock, par value $0.01 per share, Series A Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The Series A Convertible Preferred Stock was convertible into shares of common stock at any time using a conversion ratio of $8.00 per share. As of April 30, 2020, all 2,504 of the Series A Convertible Preferred Stock had converted to 313,000 shares of the Company's common stock.

•Gross proceeds from the sale of Class A Units and Class B Units totaled $5,750.

In the concurrent private placement, certain existing shareholders purchased the following securities:

•5,750 Units, priced at $1,000 per unit, each unit consisting of one share of the Company's Series B Convertible Preferred Stock, par value $0.01 per share, contingently convertible into 125 shares of common stock at an exercise price of $8.00 per share, Series A Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering.

•At issuance, the Series B Convertible Preferred Stock had various superior rights to the Company's other securities, including the Series A Convertible Preferred Stock sold under the public portion of the concurrent offerings. Upon issuance, the Series B Convertible Preferred Stock was contingently redeemable for cash at the election of the holders if the Charter Amendment to effect a reverse stock split did not occur within twelve months of issuance. The Series B Convertible Preferred Stock also had cumulative quarterly dividend rights, payable starting March 31, 2020, pursuant to which the Series B Convertible Preferred stockholders were entitled to receive a dividend initially equal to 2 percent of stated value, plus all accrued and unpaid dividends. The dividends were payable in additional shares of Series B Convertible Preferred Stock and the dividend rate increased 2 percent quarterly as long as the Series B Convertible Preferred Stock remained outstanding. In the event of a liquidation of the Company, the Series B Convertible Preferred stockholders would be paid the greater of the stated value of the shares plus accrued dividends to the point of liquidation prior to payment to junior securities holders, including common stock and the amount payable on the number of shares of common stock the Series B Convertible Preferred Stock holders would be entitled to on an as-if converted basis.

•Gross proceeds from the private placement also totaled $5,750.

As of the November 19, 2019 closing date of the two offerings, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the Series B Convertible Preferred Stock sold in the private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued under both the public and the private offerings. The Series B Convertible Preferred Shares and the Series A Warrants and Series B Warrants were not convertible or exercisable until more shares of common stock became available for issuance through the Company's filing of the Charter Amendment for the reverse stock split. Upon the filing of the Charter Amendment on January 15, 2020, the Series B Convertible Preferred Stock sold in the private placement automatically converted into 718,750 shares of common stock and the Series A Warrants and Series B Warrants issued in both offerings became eligible for exercise.

Until their conversion to common stock, the Company recorded the Series A Convertible Preferred Stock as permanent equity within the Company's balance sheet. The contingent redemption rights of the Series B Convertible Preferred stockholders were judged to be outside of the Company's control and resulted in their classification as temporary equity within the Company's balance sheet until their automatic conversion to common shares in January 2020.

The Series A Warrants and Series B Warrants are free standing financial instruments, legally detachable and separately exercisable from the common and preferred stock issued in the concurrent offerings. At the time of their issuance, the Company determined that all of the warrants should be classified as a warrant liability recognized at an inception date fair value of $24,518 due to the insufficiency of common shares available to permit their exercise. As the proceeds from the offerings were less than the fair value of their respective warrants, the warrants were recorded at their full fair value and the difference between the fair value and the cash proceeds of $13,018 were recorded to other income (expense) in the Company's consolidated statement of operations during the year ended December 31, 2019. No residual offering proceeds remained to be allocated to the common and preferred shares sold in the offering.

The Company re-measured the fair value of the warrants on December 31, 2019 and again on January 15, 2020 (the date of filing the Charter Amendment to increase available shares of common stock), resulting in, respectively, the recognition of a gain of $9,541 followed by a loss of $957, due to the change in fair value at each valuation date. By filing the Charter Amendment and enacting the 1-for-40 Reverse Stock Split, the Company's outstanding common shares were reduced by a divisible factor of 40 while authorized common shares remained at the current 60 million shares. As a result of this corporate action, sufficient shares of authorized, but unissued shares of common stock became available for Series A and Series B warrant holders to exercise their warrants resulting in their reclassification from warrant liability to equity in the Company's consolidated balance sheet.

At closing, the proceeds of the combined offerings were allocated solely to the liability classified warrants, and as a consequence, the offering costs of $1,254 were immediately expensed to other income (expense) in the consolidated statement of operations for the year ended December 31, 2019 in accordance with accounting guidance.

March 2019 Registered Direct Offering

On March 18, 2019, the Company completed a registered direct offering of its common stock. Proceeds from the transaction were $2,932 before issuance costs of $349. Investors participating in the transaction purchased a total of 60,541 shares of common stock at a price of $48.40 per share.

Preferred Stock

The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

Description of Series A Convertible Preferred Stock

The November 2019 public offering of the Company's securities included the issuance of 2,504 shares of Series A Convertible Preferred Stock. Each Series A Convertible Preferred Share was convertible into 125 shares of common stock at a conversion price of $8.00 per share. As of April 30, 2020, all 2,504 shares of the Series A Convertible Preferred Stock had converted to 313,000 shares of common stock.

Description of Series B Convertible Preferred Stock

The November 2019 private offering of the Company's securities included the issuance of 5,750 shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock was convertible into 125 shares of common stock at a conversion price of $8.00 per share. All of the Series B Convertible Preferred Stock converted automatically to 718,750 shares of common stock on January 15, 2020, upon the Company's filing of a Charter Amendment for the reverse stock split described above.

When converted, the shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock were restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the board of directors.

Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2020:


Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
November 2019 Public Offering - Series A	580,727	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	649,477	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,843,699

Warrant Exercises

During the year ended December 31, 2020, a total of 207,296 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $1,658 in cash proceeds.

After December 31, 2020, and through March 15, 2021, Yield10 received a further $3,856 in cash from the exercise of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering.

Reserved Shares

The following common stock shares were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs"), conversion of outstanding Series A Convertible Preferred Stock and conversion of outstanding warrants:


	December 31, 2020	December 31, 2019
Stock Options	339,108	62,065
RSUs	8,500	—
Series A Convertible Preferred Stock - November 2019 Public Offering	—	99,500
Warrants	2,843,699	175,995
Total number of common shares reserved for future issuance	3,191,307	337,560

As of December 31, 2019, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the 718,750 Series B Convertible Preferred Stock sold in the November 2019 private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued in the concurrent public and private offerings. Shares of common stock became available for issuance through the Company's filing of a Charter Amendment for the reverse stock split on January 15, 2020. Because they were not convertible or exercisable as of December 31, 2019, the Series B Convertible Preferred Stock and the Series A Warrants and Series B Warrants were excluded from the table of reserved shares shown above at December 31, 2019.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock Option Plans

The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan"). No further grants or awards were subsequently made under the 2006 Plan. A total of 3,662 options were awarded from the 2006 Plan and as of December 31, 2020, 422 of these options remain outstanding and eligible for future exercise.

The 2014 Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan, which was amended in May 2020 (the "2018 Stock Plan"). A total of 16,896 options have been awarded from the 2014 Plan and as of December 31, 2020, 16,322 of these options remain outstanding and eligible for future exercise. A total of 3,619 restricted stock awards have been awarded from the 2014 Plan and as of December 31, 2020, all of these restricted stock awards are vested and outstanding. No further stock awards may be issued from the 2014 Plan.

The 2018 Stock Plan initially reserved for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, non-qualified stock options, stock grants and other stock-based awards. In accordance with the terms of the 2018 Stock Plan, the Company's Board of Directors approved the addition of shares to the 2018 Stock Plan on the first day of January 2019, 2020 and 2021 in amounts equal to 5% of the outstanding shares of the Company's common stock on the day prior to the increase. Total shares added to the 2018 Plan from these annual additions have amounted to 225,906. At its annual meeting of stockholders on May 19, 2020, stockholders approved an amendment to the 2018 Plan to add 250,000 more shares to the plan. As of December 31, 2020, a total of 340,305 options and restricted stock awards have been issued from the 2018 Stock Plan, and as of that date, 330,385 options and restricted stock awards remain outstanding.

Expense Information for Stock Awards

The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $739 and $656 for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020, there was approximately $1,968 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 3.18 years.

Stock Options

Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of one to four years from the date of hire for new employees, or date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance. The Company's policy is to issue new shares upon the exercise of stock options.

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:


	Number of Shares	Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2019	62,065	$	178.95
Granted	278,421	5.95
Exercised	—	—
Forfeited	(721)	48.40
Expired	(657)	2,654.98
Balance at December 31, 2020	339,108	32.39		9.02	$	—
Vested and expected to vest at December 31, 2020	339,108	32.39		9.02	$	—
Exercisable at December 31, 2020	86,933	99.41		8.18	$	—

The weighted average grant date fair value per share of options granted during fiscal years 2020 and 2019, was $5.31, and $30.77, respectively. No options were exercised during 2020 and 2019, and therefore the intrinsic value for exercised options during the two years was not applicable. The weighted average remaining contractual term for options outstanding as of December 31, 2020 was 9.02 years.

For the years ended December 31, 2020, and 2019, the Company determined the fair value of stock options using the Black-Scholes option pricing model with the following assumptions for option grants, respectively:


	Year Ended December 31,
	2020	2019
Expected dividend yield	—	—
Risk-free rate	0.5% - 1.9%	1.7% - 2.5%
Expected option term (in years)	6.1 - 10.0	6.0 - 10.0
Volatility	111% - 129%	107% - 124%

The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history. The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option. The expected term of the options is based upon evaluation of historical and expected future exercise behavior.

The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest. The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.

Restricted Stock Units ("RSUs")

The Company records stock compensation expense for RSUs on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value. As RSUs vests, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. The Company then pays the minimum required income tax for the employees. During the years ended December 31, 2020 and December 31, 2019, the Company withheld vested shares with a fair value of $17 and $4 to pay for minimum tax withholding associated with RSU vesting.

A summary of RSU activity for the year ended December 31, 2020 is as follows:


	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2019	—
Awarded	17,000
Released	(8,500)
Forfeited	—
Outstanding at December 31, 2020	8,500	0.12

Weighted average remaining recognition period (years)	0.12

The Company did not award any RSUs during the year ended December 31, 2019.

Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

LEASES

As a lessee, the Company follows the lease accounting guidance codified in ASC 842, Leases. Under ASC 842, a lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease. Any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. The Company's existing lease arrangements meet the standards for operating lease classification.

Under ASC 842, a lease liability is recorded on the commencement date of a lease and is calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company has adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.

In November 2019, the Company entered into a lease modification with the landlord for its headquarters located in Woburn, Massachusetts, as described further below. As a result of returning 7,409 square feet of space to the landlord for the remaining term of the lease, the Company remeasured and reduced its associated right-of-use asset and lease liability by $1,011 and $1,401, respectively, and recorded a charge to lease expense of $390.

Maturity Analysis of Lease Liabilities

At December 31, 2020, the Company's lease liabilities will mature as follows:


Year ended December 31,	Undiscounted Cash Flows
2021	$	704
2022	726
2023	749
2024	771
2025	793
Thereafter	747
Total undiscounted future lease payments	4,490
Discount	(870)
Total lease liabilities	$	3,620
Short-term lease liabilities	$	457
Long-term lease liabilities	$	3,163

At December 31, 2020, the Woburn, Massachusetts facility is the only lease included within the Company's right-of-use assets and corresponding lease liabilities.

Quantitative Disclosure of Lease Costs


	Year Ended December 31,
	2020		2019
Lease cost:
Operating lease cost	$	688	$	640
Short-term lease cost	676		569
Sublease income	(560)		(539)
Total lease cost, net	$	804	$	670

Operating lease cost of $640 for the year ended December 31, 2019 is shown net of a reduction of $390 related to the Company's modification to its Woburn, Massachusetts lease described above.


Other information as of:	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)	5.9	6.7
Weighted-average discount rate	7.25%	7.24%

Real Estate Leases

During 2016, the Company entered into a lease agreement for its headquarters, pursuant to which the Company leased approximately 29,622 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. The lease agreement does not include any options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain taxes and operating costs associated with the premises throughout the term of the lease. During the buildout of the rented space, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that result in increased rental payments by the Company. Upon the adoption of ASC 842, these improvements were recorded as a reduction in the valuation of the right-of-use asset.

In November 2019, the Company entered into a modification to the Woburn lease in which Yield10 returned 7,409 square feet of underutilized space to the landlord for the remaining term of the lease. In exchange for returning the space, the landlord agreed to fund modifications and upgrades to the remaining office space retained by the Company. The modifications were completed in February 2020, and after that point the Company has no further financial obligations for the vacated space and lease rental charges, including utility, maintenance and real estate tax charges. The security deposit was also proportionally reduced from $307 to $229. During the first quarter of 2020, the Company wrote off $206 in leasehold improvements and office furniture, net of proceeds, associated with the returned space.

In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The CJ sublease is unaffected by the Company's 2019 lease modification with the landlord and remains coterminous with the Company's master lease. CJ will pay pro rata rent and operating expenses equal to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $4,490 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

Through May 2020, the Company leased approximately 13,702 square feet of unused office and laboratory space in Lowell, Massachusetts. The lease terminated in accordance with the terms of the lease agreement and the facility has been returned to the landlord. No further expenses are anticipated under this lease.

The Company's wholly-owned subsidiary, Metabolix Oilseeds, Inc. ("MOI"), located in Saskatoon, Saskatchewan, Canada, leases approximately 7,000 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. These leases do not contain renewal or early termination options. MOI's leases for these facilities generally have terms of one year and are extended annually through amendment. Most of these leases will expire on May 31, 2021, unless further amended, and others will expire on various dates through September 30, 2021.

Cares Act Loan	12 Months Ended
Cares Act Loan	Dec. 31, 2020
Debt Disclosure [Abstract]
Cares Act Loan	Cares Act LoanDuring April 2020, the Company received $333 in loan proceeds through the Paycheck Protection Program Flexibility Act ("PPP"), established pursuant to the CARES Act. Under the CARES Act and the PPP, a borrower may apply for and be granted forgiveness for all or a part of its PPP loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the borrower during the twenty-four-week period after the loan origination for certain purposes including payroll costs, rent payments on certain leases, and certain qualified utility payments. Yield10 utilized the entire PPP Loan amount for qualifying expenses and applied for loan forgiveness, receiving a favorable determination in November 2020 for the full amount of the loan. As a result, the Company recorded the $333 as loan forgiveness income within other income (expense) in its consolidated statement of operations for the year ended December 31, 2020.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes and Deferred Tax Assets and Liabilities

The components of loss from operations before provision for income taxes consist of the following:


	Year Ended December 31,
	2020		2019
Domestic	$	(10,287)	$	(13,394)
Foreign	137		184
Net loss from operations before income tax (provision) benefit	$	(10,150)	$	(13,210)

The components of the income tax benefit consisted of the following for the years ended December 31, 2020 and 2019:


	Year Ended December 31,
	2020		2019
Current Tax Benefit:
Federal	$	—	$	—
State	—		—
Foreign	—		—
Total current	—		—

Deferred Tax Benefit:
Federal	—		—
State	—		—
Foreign	56		(254)
Total deferred	56		(254)
Total tax provision (benefit)	$	56	$	(254)

Significant components of the Company's deferred tax assets are as follows:


	Year Ended December 31,
	2020		2019
Deferred Tax Assets:
Net operating loss carryforward	$	28,425	$	25,799
Capitalization of research and development expense	938		1,162
Credit carryforwards	2,431		2,332
Capital loss carryover	646		646
Stock compensation	764		915
Lease liability	993		1,141
Other temporary differences	338		303
Total deferred tax assets.	34,535		32,298
Valuation allowance	(33,377)		(30,953)
Net deferred tax assets	1,158		1,345
Deferred Tax Liabilities:
Depreciation	(216)		(246)
Right-of-use asset	(741)		(845)
Net deferred taxes	$	201	$	254

Tax Rate

The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:


	Year Ended December 31,
	2020		2019
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	5.1	%	2.0	%
Permanent differences	0.2	%	(0.4)	%
Tax credits	1.7	%	0.6	%
Canada credit audit adjustment	0.0	%	(2.6)	%
Foreign rate differential	(0.1)	%	(0.1)	%
Non-deductible equity transactions	(2.0)	%	(7.5)	%
Stock compensation	(2.6)	%	(0.9)	%
Other	0.0	%	(0.7)	%
Change in valuation allowance	(23.9)	%	(9.5)	%
Total	(0.6)	%	1.9	%

Tax Attributes

At December 31, 2020, the Company had U.S. net operating loss carryforwards (NOLs) for federal and state income tax purposes of approximately $105,163 and $100,333, respectively. Included in the $105,163 of federal net operating losses are losses of $27,354 that will carry forward indefinitely. The remaining federal net operating losses of $77,809 will begin to expire in 2033. The Company's state net operating loss carryforwards will begin to expire on various dates through 2040. The Company also had available research and development and investment tax credits for federal and state income tax

purposes of approximately $1,522 and $896, respectively. These federal and state credits will begin to expire on various dates through 2040. In Canada, the Company has cumulative research tax credits totaling $201 that will begin to expire on various dates through 2035.

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the U.S. net deferred tax assets. Alternatively, the Company has concluded that it is more likely than not that the net deferred tax assets of its wholly-owned Canadian subsidiary, Metabolix Oilseeds, Inc. ("MOI"), totaling $201, will be recognized in the future as a result of annual taxable income generated through MOI's research services and transfer pricing agreements with its U.S. parent.

Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed an evaluation of its ownership changes through December 31, 2015 and determined that an ownership change occurred on August 22, 2014 in connection with an equity offering. As a consequence of this ownership change, the Company's NOLs, tax credit carryforwards and other tax deductions allocable to the tax periods preceding the ownership change became subject to limitation under Section 382. The Company has reduced its associated deferred tax assets accordingly. The Company has not yet completed an evaluation of ownership changes for the years 2016 through 2020. To the extent an ownership change occurs in the future, the net operating loss, credit carryforwards and other deferred tax assets may be subject to further limitations.

Other

The tax years 2017 through 2020 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S. The statute of limitations for net operating losses utilized in future years will remain open beginning in the year of utilization.

The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2020 and 2019, the Company had no accrued interest or penalties recorded related to uncertain tax positions.

The CARES Act was signed into law on March 7, 2020, and contained specific relief and stimulus measures. The Company has reviewed the impact of the CARES Act and has determined that it does not have a material impact on the Company's tax provision.

No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 Bioscience, Inc. or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant. As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings. A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries. Unremitted earnings at December 31, 2020 and December 31, 2019 approximated $999 and $778, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2020
Retirement Benefits [Abstract]
Employee Benefits	Employee BenefitsThe Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations. The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 20,788, and 2,885 shares of common stock during the years ended December 31, 2020, and December 31, 2019, respectively, and recorded $108, and $98, respectively, of related expense. Company contributions are fully vested upon issuance.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

U.S. Department of Energy Grants	12 Months Ended
U.S. Department of Energy Grants	Dec. 31, 2020
Research and Development Arrangement with Federal Government [Abstract]
U.S. Department of Energy Grants	Government Research Grants On May 20, 2020, MOI, the Company’s wholly-owned Canadian research subsidiary, received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC"). The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises. Under the terms of the agreement, NRC agreed to contribute up to a maximum of $67 for payroll costs incurred by MOI during the period April - June, 2020. During the second quarter of 2020, MOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award. On December 3, 2020, MOI received a second IRAP funded research grant with a similar objective of providing financial research assistance. Under the terms of this second grant, NRC agreed to contribute up to a maximum of $86 for payroll costs incurred by MOI during the period July - December, 2020. The full amount of the grant was recognized as grant revenue during the fourth quarter and is recorded as accounts receivable in the Company's consolidated balance sheet at December 31, 2020. During 2018 the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy funded grant entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil." The Company's participation under this projected five-year grant is being awarded on an annual basis with the first year commencing on September 15, 2017. Cumulative funding for this sub-award in the amount of $2,403 has been appropriated by the U.S. Congress through the fourth contractual year ending in September 2021. The Company anticipates that the final option year through September 14, 2022 will be awarded to Yield10 during 2021 for total sub-award funding of $2,957, provided the U.S. Congress continues to appropriate funds for the program, the Company is able to make progress towards meeting grant objectives and it remains in compliance with other terms and conditions of the sub-award. During the years ended December 31, 2020 and December 31, 2019, the Company recognized $646 and $806, respectively, in revenue related to this sub-award.

Geographic Information

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Geographic Information

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:


	U.S.		Canada		Eliminations		Total
Year Ended December 31, 2020
Net revenues to unaffiliated customers	$	646	$	153	$	—	$	799
Inter-geographic revenues	—		1,857		(1,857)		—
Net revenues	$	646	$	2,010	$	(1,857)	$	799
Identifiable long-lived assets	$	866	$	55	$	—	$	921
Year Ended December 31, 2019
Net revenues to unaffiliated customers	$	806	$	—	$	—	$	806
Inter-geographic revenues	—		1,883		(1,883)		—
Net revenues	$	806	$	1,883	$	(1,883)	$	806
Identifiable long-lived assets	$	1,186	$	57	$	—	$	1,243

Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled. During 2020, grant revenue earned from the Company's Michigan State University sub-award totaled $646, or 80.9% of the Company's total revenue. Revenue earned from the Company's Canadian IRAP grants totaled $153, or 19.1% of the Company's total 2020 revenue.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 3, 2021, the Company completed a public offering of its common stock, raising $11,996, net of estimated offering costs of $744. In the offering, 1,040,000 shares of common stock were sold at an issuance price of $12.25. After December 31, 2020 and through March 15, 2021, warrant holders exercised 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering, providing $3,856 in cash proceeds.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Principles of ConsolidationThe Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.

Use of Estimates

Cash and Cash Equivalents

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Restricted Cash

Amounts included in restricted cash represent those required to be set aside by contractual agreement.

Investments

Foreign Currency Translation

Comprehensive Income (Loss)

Concentration of Credit Risk

Fair Value Measurements

Segment Information

Segment InformationThe accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. As of December 31, 2020, and December 31, 2019, less than 10% of the Company's combined total assets were located outside of the United States.

Property and Equipment


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Impairment of Long-Lived Assets

Grant Revenue

Research and Development

General, and Administrative Expenses

General and Administrative Expenses

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

Basic and Diluted Net Loss per Share

excludes 481,973 shares of common stock issued after December 31, 2020 from the exercise of outstanding warrants by warrant holders. See Note 17 - Subsequent Events.

Income Taxes

See Note 13 for further discussion of income taxes. The Company had no amounts recorded for any unrecognized tax benefits as of December 31, 2020 and 2019.

Recent Accounting Standards Changes

The following new pronouncement is not yet effective but may impact the Company's financial statements in the future.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Reconciliation of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed consolidated balance sheets included herein:


	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	3,423	$	5,417
Restricted cash	264		332
Total cash, cash equivalents and restricted cash	$	3,687	$	5,749

Schedule of estimated useful life of assets used to compute depreciation using the straight-line method

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Property and equipment consist of the following:


	Year ended December 31,
	2020		2019
Equipment	$	766	$	852
Furniture and fixtures	43		119
Leasehold improvements	1,414		1,748
Software	22		53
Total property and equipment, at cost	2,245		2,772
Less: accumulated depreciation	(1,324)		(1,529)
Property and equipment, net	$	921	$	1,243

Schedule of shares used to calculate diluted earnings per share


	Year Ended December 31,
	2020	2019
Options	218,964	54,430
Restricted stock awards	11,775	42
Series A Convertible Preferred Stock	12,737	18,420
Series B Convertible Preferred Stock	31,421	82,705
Warrants	2,843,699	180,467
Total	3,118,596	336,064

Investments (Tables)

12 Months Ended

Dec. 31, 2020

Investments, Debt and Equity Securities [Abstract]

Schedule of investment holdings

The Company's investments consist of the following:


	Accumulated Cost at December 31, 2020		Unrealized				Market Value at December 31, 2020
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	6,279	$	—	$	—	$	6,279
Total	$	6,279	$	—	$	—	$	6,279


	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair value measurement inputs


At December 31, 2019	Series A Warrants	Series B Warrants
Fair market of common stock (per share)	$6.86	$6.86
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%


At January 15, 2020	Series A Warrants	Series B Warrants
Fair market of common stock (per share)	$3.77	$3.77
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

Assets and liabilities measured at fair value on a recurring basis

s below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.


	Fair value measurements at December 31, 2020
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2020
Assets
Cash equivalents:
Money market funds	$	2,873	$	—	$	—	$	2,873

Short-term investments:
U.S. government and agency securities	—		6,279		—		6,279
Total assets	$	2,873	$	6,279	$	—	$	9,152


	Fair value measurements at December 31, 2019
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977

Reconciliation of beginning and ending balances for the Level 3 warrant liability


	Year ended December 31,
	2020		2019
Warrant liability, beginning of year	$	14,977	$	—
Warrants issued and classified as Level 3	—		24,518
Recognized gain (loss) from mark-to-market adjustment at December 31, 2019 balance sheet date	—		(9,541)
Recognized gain (loss) from mark-to-market adjustment prior to reclassification of warrant liability to equity	957		—
Reclassification from warrant liability to equity	(15,934)		—
Warrant liability, end of year	$	—	$	14,977

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of components of property and equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Property and equipment consist of the following:


	Year ended December 31,
	2020		2019
Equipment	$	766	$	852
Furniture and fixtures	43		119
Leasehold improvements	1,414		1,748
Software	22		53
Total property and equipment, at cost	2,245		2,772
Less: accumulated depreciation	(1,324)		(1,529)
Property and equipment, net	$	921	$	1,243

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:


	Year ended December 31,
	2020		2019
Employee compensation and benefits	$	620	$	669
Leased facilities	188		51
Professional services	235		327
Other	254		279
Total accrued expenses	$	1,297	$	1,326

Capital Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Information with regard to outstanding warrants to purchase common stock

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2020:


Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
November 2019 Public Offering - Series A	580,727	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	649,477	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,843,699

Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance


	December 31, 2020	December 31, 2019
Stock Options	339,108	62,065
RSUs	8,500	—
Series A Convertible Preferred Stock - November 2019 Public Offering	—	99,500
Warrants	2,843,699	175,995
Total number of common shares reserved for future issuance	3,191,307	337,560

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of the activity related to the shares of common stock covered by outstanding options under the plans

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:


	Number of Shares	Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2019	62,065	$	178.95
Granted	278,421	5.95
Exercised	—	—
Forfeited	(721)	48.40
Expired	(657)	2,654.98
Balance at December 31, 2020	339,108	32.39		9.02	$	—
Vested and expected to vest at December 31, 2020	339,108	32.39		9.02	$	—
Exercisable at December 31, 2020	86,933	99.41		8.18	$	—

Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model


	Year Ended December 31,
	2020	2019
Expected dividend yield	—	—
Risk-free rate	0.5% - 1.9%	1.7% - 2.5%
Expected option term (in years)	6.1 - 10.0	6.0 - 10.0
Volatility	111% - 129%	107% - 124%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of RSU activity for the year ended December 31, 2020 is as follows:


	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2019	—
Awarded	17,000
Released	(8,500)
Forfeited	—
Outstanding at December 31, 2020	8,500	0.12

Weighted average remaining recognition period (years)	0.12

The Company did not award any RSUs during the year ended December 31, 2019.

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Maturity analysis of lease liabilities

At December 31, 2020, the Company's lease liabilities will mature as follows:


Year ended December 31,	Undiscounted Cash Flows
2021	$	704
2022	726
2023	749
2024	771
2025	793
Thereafter	747
Total undiscounted future lease payments	4,490
Discount	(870)
Total lease liabilities	$	3,620
Short-term lease liabilities	$	457
Long-term lease liabilities	$	3,163

Quantitative disclosure of lease costs

Quantitative Disclosure of Lease Costs


	Year Ended December 31,
	2020		2019
Lease cost:
Operating lease cost	$	688	$	640
Short-term lease cost	676		569
Sublease income	(560)		(539)
Total lease cost, net	$	804	$	670

Operating lease cost of $640 for the year ended December 31, 2019 is shown net of a reduction of $390 related to the Company's modification to its Woburn, Massachusetts lease described above.


Other information as of:	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)	5.9	6.7
Weighted-average discount rate	7.25%	7.24%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of components of profit (loss) before provision for income taxes

The components of loss from operations before provision for income taxes consist of the following:


	Year Ended December 31,
	2020		2019
Domestic	$	(10,287)	$	(13,394)
Foreign	137		184
Net loss from operations before income tax (provision) benefit	$	(10,150)	$	(13,210)

Components of income tax benefit

The components of the income tax benefit consisted of the following for the years ended December 31, 2020 and 2019:


	Year Ended December 31,
	2020		2019
Current Tax Benefit:
Federal	$	—	$	—
State	—		—
Foreign	—		—
Total current	—		—

Deferred Tax Benefit:
Federal	—		—
State	—		—
Foreign	56		(254)
Total deferred	56		(254)
Total tax provision (benefit)	$	56	$	(254)

Schedule of significant components of the Company's net deferred tax asset

Significant components of the Company's deferred tax assets are as follows:


	Year Ended December 31,
	2020		2019
Deferred Tax Assets:
Net operating loss carryforward	$	28,425	$	25,799
Capitalization of research and development expense	938		1,162
Credit carryforwards	2,431		2,332
Capital loss carryover	646		646
Stock compensation	764		915
Lease liability	993		1,141
Other temporary differences	338		303
Total deferred tax assets.	34,535		32,298
Valuation allowance	(33,377)		(30,953)
Net deferred tax assets	1,158		1,345
Deferred Tax Liabilities:
Depreciation	(216)		(246)
Right-of-use asset	(741)		(845)
Net deferred taxes	$	201	$	254

Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes

The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:


	Year Ended December 31,
	2020		2019
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	5.1	%	2.0	%
Permanent differences	0.2	%	(0.4)	%
Tax credits	1.7	%	0.6	%
Canada credit audit adjustment	0.0	%	(2.6)	%
Foreign rate differential	(0.1)	%	(0.1)	%
Non-deductible equity transactions	(2.0)	%	(7.5)	%
Stock compensation	(2.6)	%	(0.9)	%
Other	0.0	%	(0.7)	%
Change in valuation allowance	(23.9)	%	(9.5)	%
Total	(0.6)	%	1.9	%

Geographic Information (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:


	U.S.		Canada		Eliminations		Total
Year Ended December 31, 2020
Net revenues to unaffiliated customers	$	646	$	153	$	—	$	799
Inter-geographic revenues	—		1,857		(1,857)		—
Net revenues	$	646	$	2,010	$	(1,857)	$	799
Identifiable long-lived assets	$	866	$	55	$	—	$	921
Year Ended December 31, 2019
Net revenues to unaffiliated customers	$	806	$	—	$	—	$	806
Inter-geographic revenues	—		1,883		(1,883)		—
Net revenues	$	806	$	1,883	$	(1,883)	$	806
Identifiable long-lived assets	$	1,186	$	57	$	—	$	1,243

Nature of Business and Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Thousands			2 Months Ended	12 Months Ended
	Feb. 03, 2021	Aug. 26, 2020	Mar. 15, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Unrestricted cash, cash equivalents and short-term investments				$ 9,702
Subsidiary, Sale of Stock [Line Items]
Proceeds from warrants exercised				$ 1,658	$ 0
Warrants
Subsidiary, Sale of Stock [Line Items]
Warrants exercised (in shares)				207,296
Proceeds from warrants exercised				$ 1,658
Public offering
Subsidiary, Sale of Stock [Line Items]
Issuance costs		$ 425
Common stock issued in offering (in shares)		835,000
Common stock price (in dollars per share)		$ 4.25
Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Proceeds from warrants exercised			$ 3,856
Subsequent Event \| Warrants
Subsidiary, Sale of Stock [Line Items]
Warrants exercised (in shares)			481,973
Subsequent Event \| Public offering
Subsidiary, Sale of Stock [Line Items]
Amount received from offering of common stock, net of issuance costs	$ 11,996
Issuance costs	$ 744
Common stock issued in offering (in shares)	1,040,000
Common stock price (in dollars per share)	$ 12.25

Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 3,423	$ 5,417
Restricted cash	264	332
Total cash, cash equivalents and restricted cash	$ 3,687	$ 5,749	$ 3,355

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2020
Equipment
Property and Equipment
Estimated Useful Life	3 years
Furniture and fixtures
Property and Equipment
Estimated Useful Life	5 years
Software
Property and Equipment
Estimated Useful Life	3 years

Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	3,118,596	336,064
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	218,964	54,430
Restricted stock awards
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	11,775	42
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	2,843,699	180,467
Series A Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	12,737	18,420
Series B Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	31,421	82,705

Summary of Significant Accounting Policies - Narrative (Details)				2 Months Ended	12 Months Ended
	Feb. 03, 2021 shares	Aug. 26, 2020 shares	Jan. 15, 2020	Mar. 15, 2021 shares	Dec. 31, 2020 USD ($) segment shares	Dec. 31, 2019 USD ($)
Concentration of credit risk
Reverse stock split, conversion ratio			0.025
Restricted cash					$ 264,000	$ 332,000
Long-term investments					0	0
Accounts and unbilled receivables					113,000	92,000
Unbilled receivables, current					27,000
Accounts receivable					$ 86,000	72,000
Number of operating segments \| segment					1
Unrecognized tax benefits					$ 0	0
Public offering
Concentration of credit risk
Common stock issued in offering (in shares) \| shares		835,000
Warrants
Concentration of credit risk
Warrants exercised (in shares) \| shares					207,296
U.S Government Grants
Concentration of credit risk
Accounts and unbilled receivables						$ 62,000
Subsequent Event \| Public offering
Concentration of credit risk
Common stock issued in offering (in shares) \| shares	1,040,000
Subsequent Event \| Warrants
Concentration of credit risk
Warrants exercised (in shares) \| shares				481,973

Investments (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Short-term Investments [Abstract]
Accumulated Cost	$ 6,279,000	$ 5,700,000
Unrealized Gain	0	0
Unrealized (Loss)	0	0
Market Value	6,279,000	5,700,000
Long-term investments	0	0
Government securities
Short-term Investments [Abstract]
Accumulated Cost	6,279,000	5,700,000
Unrealized Gain	0	0
Unrealized (Loss)	0	0
Market Value	$ 6,279,000	$ 5,700,000

Fair Value Measurements - Narrative (Details) $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 15, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Nov. 19, 2019 USD ($)
Fair Value Disclosures [Abstract]
Warrant liability	$ 15,934		$ 0	$ 14,977	$ 24,518
Gain (loss) from change in fair value or warrants	$ (957)	$ (9,541)	$ 957	$ (9,541)
Reverse stock split, conversion ratio	0.025

Fair Value Measurements - Fair Value Measurement Inputs (Details)	Dec. 31, 2020 $ / shares	Jan. 15, 2020 $ / shares	Nov. 19, 2019
Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term			2 years 6 months
Series A Warrants \| Fair market value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	6.86	3.77
Series A Warrants \| Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	2 years 3 months 18 days	2 years 3 months 18 days
Series A Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0162	0.0162
Series A Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.27	1.27
Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term			7 years 6 months
Series B Warrants \| Fair market value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	6.86	3.77
Series B Warrants \| Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	7 years 3 months 18 days	7 years 3 months 18 days
Series B Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0183	0.0183
Series B Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.15	1.15

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jan. 15, 2020	Dec. 31, 2019	Nov. 19, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 6,279		$ 5,700
Warrant liability	0	$ 15,934	14,977	$ 24,518
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	6,279		5,700
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	9,152		10,072
Warrant liability			14,977
Total liabilities			14,977
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	6,279		5,700
Fair Value, Measurements, Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,873		2,622
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			1,750
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	2,873		2,622
Warrant liability			0
Total liabilities			0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,873		2,622
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	6,279		7,450
Warrant liability			0
Total liabilities			0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	6,279		5,700
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			1,750
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0		0
Warrant liability			14,977
Total liabilities			14,977
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			$ 0

Fair Value Measurements - Level 3 Rollforward of Warrant Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Warrant liability, beginning of year	$ 14,977	$ 0
Warrants issued and classified as Level 3	0	24,518
Recognized gain (loss) from mark-to-market adjustments	957	(9,541)
Reclassification from warrant liability to equity	(15,934)	0
Warrant liability, end of year	$ 0	$ 14,977

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, net
Total property and equipment, at cost	$ 2,245	$ 2,772
Less: accumulated depreciation	(1,324)	(1,529)
Property and equipment, net	921	1,243
Depreciation	182	203
Equipment
Property and equipment, net
Total property and equipment, at cost	766	852
Furniture and fixtures
Property and equipment, net
Total property and equipment, at cost	43	119
Leasehold improvements
Property and equipment, net
Total property and equipment, at cost	1,414	1,748
Software
Property and equipment, net
Total property and equipment, at cost	$ 22	$ 53

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 620	$ 669
Leased facilities	188	51
Professional services	235	327
Other	254	279
Total accrued expenses	$ 1,297	$ 1,326

Commitments and Contingencies (Details) - Collaborative Arrangement - USD ($) $ in Thousands	Nov. 12, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Quarterly research funding and option fees	$ 31
Total research funding and option fees	$ 250	$ 219
Term of agreement	2 years
Term of option for license agreement	2 years

Capital Stock and Warrants - Narrative (Details) $ / shares in Units, $ in Thousands						1 Months Ended	2 Months Ended	3 Months Ended	12 Months Ended
	Feb. 03, 2021 USD ($) $ / shares shares	Aug. 26, 2020 USD ($) $ / shares shares	Jan. 15, 2020 USD ($) shares	Nov. 19, 2019 USD ($) $ / shares shares	Mar. 18, 2019 USD ($) $ / shares shares	Dec. 31, 2017 shares	Mar. 15, 2021 USD ($) shares	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	Apr. 30, 2020 shares
Class of Stock [Line Items]
Proceeds from Issuance of Warrants \| $				$ 13,018
Change in fair value of warrants \| $			$ (957)					$ (9,541)	$ 957	$ (9,541)
Temporary Equity, Number Of Shares Of Common Stock Issuable For Each Share Upon Conversion				125
Temporary Equity, Conversion Price \| $ / shares				$ 8.00
Temporary Equity, Shares Issued, Price Per Share \| $ / shares				$ 1,000
Number Of Shares Of Convertible Preferred Stock Included In Each Unit Of Temporary Equity				1
Reverse stock split, conversion ratio			0.025
Common stock, shares authorized (in shares)			60,000,000						60,000,000	60,000,000
Gross proceeds from transaction \| $				$ 11,500
Temporary Equity, Initial Dividend Rate				2.00%
Temporary Equity, Annual Increase In Dividend Rate				2.00%
Number of securities called by warrants (in shares)				2,875,000					2,843,699
Preferred stock, shares authorized									5,000,000
Preferred stock, par value per share (in dollars per share) \| $ / shares									$ 0.01
Warrant liability (Note 9) \| $			$ 15,934	$ 24,518					$ 0	$ 14,977
Common stock, par value per share (in dollars per share) \| $ / shares				$ 0.01					$ 0.01	$ 0.01
Issuance of preferred stock in connection with private offering (in shares)				5,750
Series B Convertible Preferred Stock, par value per share (in dollars per share) \| $ / shares				$ 0.01					$ 0.01	$ 0.01
Proceeds from warrants exercised \| $									$ 1,658	$ 0
Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)									1,348,285
Conversion of Stock, Shares Issued			718,750
Conversion of Stock, Shares Issued, Cumulative									313,000		313,000
Warrants
Class of Stock [Line Items]
Warrants exercised (in shares)									207,296
Proceeds from warrants exercised \| $									$ 1,658
Series A Warrants
Class of Stock [Line Items]
Exercise price of warrants (in USD per share) \| $ / shares				$ 8.00
Warrants, expected term				2 years 6 months
Series B Warrants
Class of Stock [Line Items]
Exercise price of warrants (in USD per share) \| $ / shares				$ 8.00
Warrants, expected term				7 years 6 months
Class A Units
Class of Stock [Line Items]
Number Of Shares Of Common Stock Included In Each Unit				1
Class A Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				1
Class B Units
Class of Stock [Line Items]
Number Of Shares Of Common Stock Included In Each Unit				1
Class B Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				125
Class B Units \| Series B Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				125
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Issuance of stock (in shares)						2,504
Convertible Preferred Stock, Number Of Common Shares Issuable For Each Share Of Preferred Stock				125
Preferred Stock Conversions, Conversion Price \| $ / shares				$ 8.00
Preferred stock, par value per share (in dollars per share) \| $ / shares				$ 0.01					$ 0.01	$ 0.01
Conversion of Stock, Shares Converted, Cumulative									2,504
Series A Convertible Preferred Stock \| Warrants \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)									207,296
Subsequent Event
Class of Stock [Line Items]
Proceeds from warrants exercised \| $							$ 3,856
Subsequent Event \| Warrants
Class of Stock [Line Items]
Warrants exercised (in shares)							481,973
Public and private offerings
Class of Stock [Line Items]
Issuance costs \| $				$ 1,254
Public offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $				$ 5,750
Issuance costs \| $		$ 425
Common stock issued in offering (in shares)		835,000
Common stock price (in dollars per share) \| $ / shares		$ 4.25
Issuance of preferred stock in connection with private offering (in shares)										5,750
Sale of Stock, Gross Consideration Received Per Transaction \| $		$ 4,045
Public offering \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										405,750
Public offering \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				405,750
Common stock price (in dollars per share) \| $ / shares				$ 8.00
Public offering \| Class B Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				2,504
Common stock price (in dollars per share) \| $ / shares				$ 1,000
Public offering \| Subsequent Event
Class of Stock [Line Items]
Issuance costs \| $	$ 744
Common stock issued in offering (in shares)	1,040,000
Common stock price (in dollars per share) \| $ / shares	$ 12.25
Registered direct offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $				$ 5,750	$ 2,932
Issuance costs \| $					$ 349
Common stock issued in offering (in shares)		396,450			60,541
Common stock price (in dollars per share) \| $ / shares		$ 4.25			$ 48.40
Sale of Stock, Gross Consideration Received Per Transaction \| $		$ 1,685
Registered direct offering \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										60,541
Over-Allotment Option [Member]
Class of Stock [Line Items]
Common stock issued in offering (in shares)		116,835
Over-Allotment Option [Member] \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				93,750

Capital Stock and Warrants - Schedule Of Warrants Issuance (Details) - $ / shares	Dec. 31, 2020	Nov. 19, 2019
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	2,843,699	2,875,000
Warrants - expiration January 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	14,270
Exercise Price (in USD per share)	$ 201.60
Warrants - expiration September 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	750
Exercise Price (in USD per share)	$ 116.00
Public offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	580,727
Exercise Price (in USD per share)	$ 8.00
Public offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	649,477
Exercise Price (in USD per share)	$ 8.00
Public offering \| Series A Warrants - expiration December 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	160,975
Exercise Price (in USD per share)	$ 90.00
Registered direct offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8.00
Registered direct offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8.00

Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	3,191,307	337,560
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	339,108	62,065
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	8,500	0
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	0	99,500
Warrants
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	2,843,699	175,995

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended		24 Months Ended
	Jan. 01, 2021	May 19, 2020	Jan. 01, 2020	Jan. 01, 2019	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2021	Dec. 31, 2018
Stock-based compensation
Unvested and outstanding restricted stock (in shares)					8,500	0
Increase in shares available for issuance, percent			5.00%	5.00%
Stock-based compensation					$ 739	$ 656
RSUs awarded (in shares)					17,000
Fair value of vested shares withheld for minimum tax withholding					$ 17	$ 4
2018 Stock Plan
Stock-based compensation
Shares reserved for issuance								32,500
Additional shares authorized		250,000
Options and restricted stock awards issued (in shares)					340,305
Options and restricted stock awards outstanding (in shares)					330,385
Stock options
Stock-based compensation
Unvested and outstanding options (in shares)					339,108	62,065
Expiration period					10 years
Weighted average grant date fair value of options granted (in dollars per share)					$ 5.31	$ 30.77
Weighted average remaining contractual term for options outstanding					9 years 7 days
Exercise of common stock options (in shares)					0	0
Stock options \| Employee and Director
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized					$ 1,968
Weighted average period over which unrecognized compensation expense is expected to be recognized					3 years 2 months 4 days
Stock options \| Minimum
Stock-based compensation
Vesting period for options granted					1 year
Stock options \| Maximum
Stock-based compensation
Vesting period for options granted					4 years
Stock options \| 2006 Plan
Stock-based compensation
Options awarded to date (in shares)					3,662
Unvested and outstanding options (in shares)					422
Stock options \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)					16,896
Unvested and outstanding options (in shares)					16,322
Restricted stock awards \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)					3,619
Restricted Stock Units (RSUs)
Stock-based compensation
Fair value of vested shares withheld for minimum tax withholding					$ 17	$ 4
Subsequent Event
Stock-based compensation
Increase in shares available for issuance, percent	5.00%
Subsequent Event \| 2018 Stock Plan
Stock-based compensation
Additional shares authorized							225,906

Stock-Based Compensation - Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Balance at the beginning of the period (in shares)	62,065
Granted (in shares)	278,421
Exercised (in shares)	0	0
Forfeited (in shares)	(721)
Expired (in shares)	(657)
Balance at the end of the period (in shares)	339,108	62,065
Vested and expected to vest at the end of the period (in shares)	339,108
Options exercisable at the end of the period (in shares)	86,933
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 178.95
Granted (in dollars per share)	5.95
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	48.40
Expired (in dollars per share)	2,654.98
Balance at the end of the period (in dollars per share)	32.39	$ 178.95
Vested and expected to vest at the end of the period (in dollars per share)	32.39
Exercisable at the end of the period (in dollars per share)	$ 99.41
Remaining Contractual Term
Balance	9 years 7 days
Vested and expected to vest	9 years 7 days
Exercisable	8 years 2 months 4 days
Aggregate Intrinsic Value
Balance	$ 0
Vested and expected to vest	0
Exercisable	$ 0

Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details) - Stock options	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Assumptions used to determine fair value of stock options
Expected dividend yield	0.00%	0.00%
Risk-free rate, minimum	0.50%	1.70%
Risk-free rate, maximum	1.90%	2.50%
Volatility, minimum	111.00%	107.00%
Volatility, maximum	129.00%	124.00%
Minimum
Assumptions used to determine fair value of stock options
Expected option term	6 years 1 month 6 days	6 years
Maximum
Assumptions used to determine fair value of stock options
Expected option term	10 years	10 years

Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)	12 Months Ended
	Dec. 31, 2020 shares
Number of RSUs
Outstanding at December 31, 2019	0
Awarded	17,000
Released	(8,500)
Forfeited	0
Outstanding at December 31, 2020	8,500
Weighted average remaining recognition period (years)	1 month 13 days

Leases - Narrative (Details) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
Leases - Narrative (Details) $ in Thousands	Nov. 30, 2019 USD ($) ft²	Oct. 31, 2016 USD ($) ft²	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($) ft²	Dec. 31, 2019 USD ($)	Dec. 31, 2017 USD ($) ft²
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets				$ 2,712	$ 3,141
Lease liabilities				3,620
Operating lease cost				688	$ 640
Undiscounted future lease payments				$ 4,490
Lease term generally				1 year
19 Presidential Way, Woburn, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Space returned to landlord (in sqft) \| ft²	7,409
Reduction in right-of-use asset, lease modification	$ 1,011
Reduction in lease liability, lease modification	1,401
Operating lease expense reduction, lease modification	390
Leased area (in sqft) \| ft²						29,622
Security deposit - letter of credit	$ 229					$ 307
Operating leases, landlord reimbursement for lease improvements						889
Operating leases, landlord reimbursement for lease improvements, additional payments						$ 444
Write off of leasehold improvements			$ 206
Subleased area (in sqft) \| ft²		9,874
Undiscounted future lease payments				$ 4,490
650 Suffolk Street, Lowell, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²				13,702
410 Downey Road and 110 Gymnasium Place
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²				7,000
CJ CheilJedang Corporation \| 19 Presidential Way, Woburn, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Security deposit - letter of credit		$ 103

Leases - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 704
2021	726
2022	749
2023	771
2024	793
Thereafter	747
Total undiscounted future lease payments	4,490
Discount	(870)
Total lease liabilities	3,620
Short-term lease liabilities	457	$ 602
Long-term lease liabilities	$ 3,163	$ 3,619

Leases - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Lease cost:
Operating lease cost	$ 688	$ 640
Short-term lease cost	676	569
Sublease income	(560)	(539)
Total lease cost, net	$ 804	$ 670
Other information as of:
Weighted-average remaining lease term	5 years 10 months 24 days	6 years 8 months 12 days
Weighted-average discount rate	7.25%	7.24%

Cares Act Loan (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Cares Act Loan (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Proceeds from PPP loan (Note 12)	$ 333	$ 333	$ 0
Loan forgiveness income		$ 333	$ 0

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Components of profit (loss) before provision for income taxes
Domestic	$ (10,287)	$ (13,394)
Foreign	137	184
Net loss from operations before income tax (provision) benefit	(10,150)	(13,210)
Current Tax Benefit:
Federal	0	0
State	0	0
Foreign	0	0
Total current	0	0
Deferred Tax Benefit:
Federal	0	0
State	0	0
Foreign	56	(254)
Total deferred	56	(254)
Total tax provision (benefit)	56	(254)
Deferred Tax Assets:
Net operating loss carryforward	28,425	25,799
Capitalization of research and development expense	938	1,162
Credit carryforwards	2,431	2,332
Capital loss carryover	646	646
Stock compensation	764	915
Lease liability	993	1,141
Other temporary differences	338	303
Total deferred tax assets.	34,535	32,298
Valuation allowance	(33,377)	(30,953)
Net deferred tax assets	1,158	1,345
Deferred Tax Liabilities:
Depreciation	(216)	(246)
Right-of-use asset	(741)	(845)
Net deferred taxes	$ 201	$ 254
Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes
Federal income tax at statutory federal rate	21.00%	21.00%
State taxes	5.10%	2.00%
Permanent differences	0.20%	(0.40%)
Tax credits	1.70%	0.60%
Canada credit audit adjustment	0.00%	(2.60%)
Foreign rate differential	(0.001)	(0.001)
Non-deductible equity transactions	(2.00%)	(7.50%)
Stock compensation	(2.60%)	(0.90%)
Other	0.00%	(0.70%)
Change in valuation allowance	(23.90%)	(9.50%)
Total	(0.60%)	1.90%

Income Taxes - Details Textual (Details) - USD ($)	12 Months Ended
Income Taxes - Details Textual (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Interest and penalties accrued	$ 0	$ 0
Provision for income taxes for undistributed earnings of foreign subsidiaries	0
Undistributed earnings of foreign subsidiaries	999,000	$ 778,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Net operating loss carryforwards	105,163,000
Net operating losses not subject to expiration	27,354,000
Net operating losses subject to expiration	77,809,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Net operating loss carryforwards	100,333,000
Research Tax Credit Carryforward \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	1,522,000
Research Tax Credit Carryforward \| State and Local Jurisdiction
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	896,000
Research Tax Credit Carryforward \| Foreign Tax Authority
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	$ 201,000

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Benefits (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Maximum contribution by participants under the 401(k) savings plan (as a percent)	60.00%
Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent	4.50%
Common stock issued under the 401(k) savings plan (in shares)	20,788	2,885
Related expense for common stock issued under the 401(k) savings plan	$ 108	$ 98

U.S. Department of Energy Grants (Details) - USD ($) $ in Thousands			12 Months Ended
	Dec. 03, 2020	May 20, 2020	Dec. 31, 2020	Dec. 31, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Government payroll reimbursement	$ 86	$ 67
Revenues			$ 799	$ 806
Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cumulative amount awarded			2,403
Total expected funding			2,957
Grant revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues			799	806
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues			$ 646	$ 806

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Geographic Information (Details) - USD ($) $ in Thousands	12 Months Ended
Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Geographic Information
Net revenues	$ 799	$ 806
Identifiable long-lived assets	921	1,243
U.S.
Geographic Information
Net revenues	646	806
Identifiable long-lived assets	866	1,186
Canada
Geographic Information
Net revenues	2,010	1,883
Identifiable long-lived assets	55	57
Eliminations
Geographic Information
Net revenues	(1,857)	(1,883)
Eliminations \| Canada
Geographic Information
Net revenues	1,857	1,883
Inter-geographic revenues
Geographic Information
Net revenues	799	806
Inter-geographic revenues \| U.S.
Geographic Information
Net revenues	646	806
Inter-geographic revenues \| Canada
Geographic Information
Net revenues	$ 153	$ 0

- Definition

+ References

+ Details

Geographic Information - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue earned
Revenues	$ 799	$ 806
Canada
Revenue earned
Revenues	$ 2,010	1,883
Customer Concentration Risk \| Revenues \| Canada
Revenue earned
Percentage of total revenue	19.10%
Customer Concentration Risk \| Revenues \| Michigan State University
Revenue earned
Percentage of total revenue	80.90%
Grant revenue
Revenue earned
Revenues	$ 799	806
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Revenue earned
Revenues	$ 646	$ 806

- Definition

+ References

+ Details

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands			2 Months Ended	12 Months Ended
	Feb. 03, 2021	Aug. 26, 2020	Mar. 15, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Proceeds from warrants exercised				$ 1,658	$ 0
Warrants
Subsequent Event [Line Items]
Warrants exercised (in shares)				207,296
Proceeds from warrants exercised				$ 1,658
Public offering
Subsequent Event [Line Items]
Issuance costs		$ 425
Common stock issued in offering (in shares)		835,000
Common stock price (in dollars per share)		$ 4.25
Subsequent Event
Subsequent Event [Line Items]
Proceeds from warrants exercised			$ 3,856
Subsequent Event \| Warrants
Subsequent Event [Line Items]
Warrants exercised (in shares)			481,973
Subsequent Event \| Public offering
Subsequent Event [Line Items]
Amount received from offering of common stock, net of issuance costs	$ 11,996
Issuance costs	$ 744
Common stock issued in offering (in shares)	1,040,000
Common stock price (in dollars per share)	$ 12.25